Drug: Myfortic (mycophenolic acid)

Manufacturer: Novartis

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication: prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, in combination with other immunosuppressants

Disease: solid organ transplant

Therapeutic Area: Solid Organ Transplant

Enrollment Form Link: www.mycophenolaterems.com

Phone Number: N/A

Fax Number: N/A

Product Website: N/A